Skip to main content
Przejdź do strony domowej Komisji Europejskiej (odnośnik otworzy się w nowym oknie)
polski pl
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-24

Molecular mechanisms of disease progression and renoprotective pharmacotherapy in children with chronic renal failure

Cel

ACE inhibitors are renoprotective in adults with chronic renal failure (CRF), but of unproven usefulness in children. In a randomised trial in 350 CRF children we will address if ACE inhibition is efficacious in slowing CRF progression in acquired and congenital nephropathies, if progression can be additionally influenced by intensified antihypertensive treatment achieving low-normal blood pressure, and which factors determine CRF progression and/or its susceptibility to ACE inhibition. Potential effects of renin-angiotensin system and PAI-l gene polymorphisms, mutations in genes defining glomerular structure or causing renal hypo/dysplasia, renal endothelnr-l turnover, plasma homocysteine and apolipoprotein phenotypes will be assessed. The cardiovascular consequences of childhood-onset CRF and renoprotective pharmacotherapy will be addressed by carotid ultrasound, echocardiography and 24-hour blood pressure monitoring.

Dziedzina nauki (EuroSciVoc)

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

Brak dostępnych danych

System finansowania

CSC - Cost-sharing contracts

Koordynator

UNIVERSITAETSKLINIKUM HEIDELBERG
Wkład UE
Brak danych
Adres
Im Neuenheimer Feld 150
69115 HEIDELBERG
Niemcy
Koszt całkowity
Brak danych

Uczestnicy (27)